In the IMAGYN050 trial, patients with ≥5% expression of PD-L1 on the immune cells, or patients with ≥1% positive tumor cells, seemed to benefit from adding atezolizumab (PD-L1 inhibitor) to chemotherapy with bevacizumab (HR=0.64 [0.43-0.96] and HR=0.41 [0.19-0.90]) (15). Here, CD274 is linked to neoplasm.